Recent Updates — IMMX

Immix Biopharma, Inc. priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share on September 29, 2026. The transaction is expected to generate gross proceeds of approximately $125 million and net proceeds of roughly $117.1 million after deducting underwriting discounts and estimated offering expenses. J.P. Morgan Securities LLC served as the sole book-running manager for the deal. The offering closed on September 30, 2026, subject to customary conditions. Immix intends to utilize the net proceeds to fund the development of its lead candidate NXC-201, as well as working capital and general corporate purposes. Immix Biopharma is a clinical-stage biotechnology company focused on developing therapies for relapsed or refractory AL Amyloidosis.

Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial for NXC-201, a CAR-T therapy for relapsed/refractory AL Amyloidosis. The data showed an 89% (40/45) complete response rate across all enrolled patients and a 100% response or minimum residual disease negativity rate among the 25 new patients. No neurotoxicity or enterocolitis was observed, with final readout and Biologics License Application submission planned for mid-2027. Immix Biopharma is a biotechnology company developing cell therapies for AL Amyloidosis.

As of July 17, 2026, Richard Graydon was terminated from the company for reasons unrelated to his activities at the firm. Management stated that his short tenure means the departure will have no material effect on business operations. Immix Biopharma, Inc. is a biopharmaceutical company.